Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale

In 2024, blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale trade exhibited significant decline, with global flows reaching $4,407,140,742 and a three-year compound annual growth rate of -1.0% (five-year: +4.1%). The all-time peak of $6,119,074,647 was recorded in 2023; the current level is 28% below that high-water mark.

Over the 13-year observation window (2012–2024), 67% of years recorded positive growth, indicating a predominantly expanding market. Trend momentum is decelerating (-10.4% acceleration).

The supply side is diversified (Herfindahl-Hirschman Index 0.103). The three largest exporters — Switzerland ($831.4M), United States ($795.0M), and Ireland ($448.2M) — collectively dominate supply flows. The leading exporter has grown at -1.7% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.106). The three largest import markets are Germany ($961.6M), Switzerland ($603.1M), and France ($479.8M). The largest importing market sources from 39 different supplying countries.

The dominant trade corridor is Switzerland → Germany at $507.3M, representing 52.8% of the importer's total demand.

The volatility score for blood, human or animal, antisera, other blood fractions and immunological products: immunological products, unmixed, not put up in measured doses or in forms or packings for retail sale is 14 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, contracting demand signals caution before committing resources. The diversified supply landscape means many competitors but also multiple entry points and buyer relationships to target.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.